Adamis Pharmaceuticals Corp (NASDAQ:ADMP) price target set to $7.00 by HC Wainwright

ME Staff
-
0

Analyst Ratings For Adamis Pharmaceuticals Corp (NASDAQ:ADMP)

Today, HC Wainwright set its price target on Adamis Pharmaceuticals Corp (NASDAQ:ADMP) to $7.00 per share.

There are 4 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Adamis Pharmaceuticals Corp (NASDAQ:ADMP) is Buy with a consensus target price of $8.6250 per share, a potential 182.79% upside.

Some recent analyst ratings include

    Recent Insider Trading Activity For Adamis Pharmaceuticals Corp (NASDAQ:ADMP)
    Adamis Pharmaceuticals Corp (NASDAQ:ADMP) has insider ownership of 10.20% and institutional ownership of 8.41%.

    • On 6/2/2016 David J Marguglio, VP, sold 700 with an average share price of $9.00 per share and the total transaction amounting to $6,300.00.
    • On 5/16/2016 David J Marguglio, SVP, sold 4,000 with an average share price of $8.08 per share and the total transaction amounting to $32,320.00.
    • On 5/9/2016 David J Marguglio, SVP, sold 4,860 with an average share price of $10.00 per share and the total transaction amounting to $48,600.00.
    • On 5/4/2016 David J Marguglio, SVP, sold 4,860 with an average share price of $9.17 per share and the total transaction amounting to $44,566.20.
    • On 5/3/2016 David J Marguglio, SVP, sold 1,140 with an average share price of $9.00 per share and the total transaction amounting to $10,260.00.
    • On 4/14/2016 David J Marguglio, SVP, sold 12,000 with an average share price of $7.52 per share and the total transaction amounting to $90,240.00.
    • On 8/14/2015 Robert B Rothermel, Director, bought 7,000 with an average share price of $3.33 per share and the total transaction amounting to $23,310.00.

    About Adamis Pharmaceuticals Corp (NASDAQ:ADMP)
    Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It also offers dry powder inhaler products consisting of albuterol (APC-2000) for the treatment of bronchospasms; fluticasone (APC-4000) for the treatment of asthma; beclomethasone (APC-1000), a metered dose inhaler product for the asthma; and naloxone injection product candidates (APC-6000) for the treatment of opioid overdose. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, ophthalmic preparations, topical compounds for pain, and men's and women's health products; and certain veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation is headquartered in San Diego, California.

    Recent Trading Activity for Adamis Pharmaceuticals Corp (NASDAQ:ADMP)
    Shares of Adamis Pharmaceuticals Corp closed the previous trading session at 3.05 up +0.100 3.39% with shares trading hands.